{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    5,
    6,
    7,
    8,
    9,
    10,
    11,
    12,
    13,
    14,
    15,
    16,
    17,
    18,
    19,
    20,
    21,
    22,
    23,
    24,
    25,
    26,
    27,
    28,
    29,
    30,
    31,
    32,
    33,
    34,
    35,
    36,
    37,
    38,
    39,
    40,
    41,
    42,
    43,
    45,
    46,
    50,
    54,
    55,
    57,
    58,
    59,
    60,
    61,
    62,
    63,
    65,
    66,
    67,
    68,
    69,
    70,
    71,
    75,
    78,
    82,
    83,
    84
  ],
  "modelUsed": "gemini-3-flash-preview",
  "data": {
    "timeAnchors": [
      {
        "id": "anchor_llm_1",
        "definition": "The date of randomization via IVRS call",
        "anchorType": "Randomization",
        "classification": "Event",
        "timelineId": null,
        "dayValue": 1,
        "sourceText": "The treatment phase begins with the randomization call to the IVRS. ... OS is defined as the time from the date of randomization to the date of death due to any cause in all randomized subjects.",
        "encounterId": null,
        "activityId": null
      },
      {
        "id": "anchor_1",
        "definition": "surgery",
        "anchorType": "Custom",
        "classification": "Conceptual",
        "timelineId": null,
        "dayValue": 1,
        "sourceText": "surgery",
        "encounterId": null,
        "activityId": null
      }
    ],
    "repetitions": [
      {
        "id": "rep_daily_1",
        "type": "Daily",
        "interval": "P1D",
        "sourceText": "od"
      },
      {
        "id": "rep_interval_1",
        "type": "Interval",
        "sourceText": "BID"
      },
      {
        "id": "rep_cycle_1",
        "type": "Cycle",
        "exitCondition": "Disease progression",
        "sourceText": "until disease progression"
      },
      {
        "id": "rep_cycle_3",
        "type": "Cycle",
        "exitCondition": "Disease progression",
        "sourceText": "until progression"
      },
      {
        "id": "rep_cycle_4",
        "type": "Cycle",
        "exitCondition": "Disease progression",
        "sourceText": "Until progression"
      },
      {
        "id": "rep_cycle_7",
        "type": "Cycle",
        "exitCondition": "Disease progression",
        "sourceText": "until unacceptable toxicity"
      },
      {
        "id": "rep_window_1",
        "type": "Continuous",
        "sourceText": "Screening Period"
      },
      {
        "id": "rep_window_2",
        "type": "Continuous",
        "sourceText": "washout period"
      },
      {
        "id": "rep_window_6",
        "type": "Continuous",
        "sourceText": "Treatment Phase"
      },
      {
        "id": "rep_window_7",
        "type": "Continuous",
        "sourceText": "treatment phase"
      },
      {
        "id": "rep_window_9",
        "type": "Continuous",
        "sourceText": "treatment period"
      },
      {
        "id": "rep_window_10",
        "type": "Continuous",
        "sourceText": "Follow-Up Phase"
      },
      {
        "id": "rep_window_11",
        "type": "Continuous",
        "sourceText": "Follow Up Phase"
      },
      {
        "id": "rep_window_12",
        "type": "Continuous",
        "sourceText": "100 days \nafter"
      },
      {
        "id": "rep_window_13",
        "type": "Continuous",
        "sourceText": "40 days post"
      },
      {
        "id": "rep_window_14",
        "type": "Continuous",
        "sourceText": "100 days post"
      },
      {
        "id": "rep_window_15",
        "type": "Continuous",
        "sourceText": "3 days \nafter"
      },
      {
        "id": "rep_window_16",
        "type": "Continuous",
        "sourceText": "3 days after"
      },
      {
        "id": "rep_llm_1",
        "type": "Interval",
        "startOffset": "P0D",
        "endOffset": "null",
        "interval": "P2W",
        "minObservations": 1,
        "exitCondition": "unacceptable toxicity or disease progression",
        "sourceText": "On treatment visits will occur at Day 1 and every 2 weeks thereafter."
      },
      {
        "id": "rep_llm_2",
        "type": "Interval",
        "startOffset": "P8W",
        "endOffset": "P48W",
        "interval": "P8W",
        "minObservations": 5,
        "exitCondition": "48 weeks reached",
        "sourceText": "Tumor imaging assessments will occur 8 weeks from the date of randomization (+/-1 wk), then every 8 weeks (+/- 1 wk) thereafter up to 48 weeks"
      },
      {
        "id": "rep_llm_3",
        "type": "Interval",
        "startOffset": "P48W",
        "endOffset": "null",
        "interval": "P12W",
        "minObservations": 1,
        "exitCondition": "disease progression or treatment is discontinued (whichever occurs later)",
        "sourceText": "then it will be every 12 weeks (+/- 1 week) until disease progression or treatment is discontinued (whichever occurs later)."
      },
      {
        "id": "rep_llm_4",
        "type": "Interval",
        "startOffset": "P100D",
        "endOffset": "null",
        "interval": "P3M",
        "minObservations": 1,
        "exitCondition": "null",
        "sourceText": "Survival status will be assessed every 3 months after follow up visits are completed"
      },
      {
        "id": "rep_llm_5",
        "type": "Continuous",
        "startOffset": "P0D",
        "endOffset": "null",
        "interval": "P1D",
        "minObservations": 1,
        "exitCondition": "unacceptable toxicity or disease progression",
        "sourceText": "Subjects will be treated until unacceptable toxicity or disease progression."
      }
    ],
    "samplingConstraints": [],
    "traversalConstraints": [
      {
        "id": "traversal_crossover_1",
        "requiredSequence": [
          "SCREENING",
          "PERIOD_1",
          "PERIOD_2",
          "END_OF_STUDY"
        ],
        "allowEarlyExit": true,
        "exitEpochIds": [
          "EARLY_TERMINATION"
        ],
        "mandatoryVisits": [
          "Screening",
          "Day 1",
          "End of Study"
        ],
        "sourceText": "washout period"
      },
      {
        "id": "traversal_1",
        "requiredSequence": [
          "SCREENING",
          "RANDOMIZATION",
          "TREATMENT",
          "FOLLOW_UP",
          "SURVIVAL_FOLLOW_UP"
        ],
        "allowEarlyExit": true,
        "exitEpochIds": [
          "EARLY_TERMINATION"
        ],
        "mandatoryVisits": [
          "Follow-up Visit 1",
          "Screening",
          "End of Study",
          "Follow-up Visit 2",
          "Day 1"
        ],
        "sourceText": "[{'condition': 'Disease progression under protocol-defined conditions', 'path': ['TREATMENT_BEYOND_PROGRESSION', 'FOLLOW_UP']}, {'condition': 'Unacceptable toxicity', 'path': ['DISCONTINUATION', 'FOLLOW_UP']}]"
      }
    ],
    "executionTypes": [
      {
        "activityId": "Ecg",
        "executionType": "Single",
        "rationale": "No strong signals detected"
      },
      {
        "activityId": "Pe",
        "executionType": "Single",
        "rationale": "No strong signals detected"
      },
      {
        "activityId": "Ae",
        "executionType": "Single",
        "rationale": "SINGLE signals: 2"
      },
      {
        "activityId": "Concomitant Medication",
        "executionType": "Recurring",
        "rationale": "RECURRING signals: 2"
      },
      {
        "activityId": "Laboratory Test",
        "executionType": "Recurring",
        "rationale": "SINGLE signals: 3; RECURRING signals: 4"
      },
      {
        "activityId": "Pharmacokinetic",
        "executionType": "Single",
        "rationale": "No strong signals detected"
      },
      {
        "activityId": "Dosing",
        "executionType": "Episode",
        "rationale": "EPISODE signals: 9"
      },
      {
        "activityId": "Imaging",
        "executionType": "Single",
        "rationale": "SINGLE signals: 3; RECURRING signals: 3"
      },
      {
        "activityId": "Biopsy",
        "executionType": "Single",
        "rationale": "SINGLE signals: 11"
      },
      {
        "activityId": "Epro",
        "executionType": "Single",
        "rationale": "SINGLE signals: 1"
      },
      {
        "activityId": "Nivolumab Administration",
        "executionType": "Recurring",
        "rationale": "Administered 240 mg IV every 2 weeks until disease progression or unacceptable toxicity."
      },
      {
        "activityId": "Sorafenib Administration",
        "executionType": "Recurring",
        "rationale": "Administered 400 mg PO BID until disease progression or unacceptable toxicity."
      },
      {
        "activityId": "Overall Survival (OS) Assessment",
        "executionType": "Window",
        "rationale": "Continuous monitoring of survival status from randomization until death or study completion."
      },
      {
        "activityId": "Objective Response Rate (ORR) Assessment",
        "executionType": "Recurring",
        "rationale": "Determined by BICR based on RECIST 1.1, which involves repeated imaging assessments at scheduled intervals."
      },
      {
        "activityId": "Confirmatory Scan for CR/PR",
        "executionType": "Episode",
        "rationale": "Conditional workflow requiring a follow-up scan only if an initial Complete Response or Partial Response is observed."
      },
      {
        "activityId": "Baseline PBMC and MDSC Collection",
        "executionType": "Single",
        "rationale": "Collected from subjects at baseline only from selected sites."
      },
      {
        "activityId": "Hepatitis D Testing",
        "executionType": "Episode",
        "rationale": "Conditional workflow performed locally if the Central Laboratory is unable to perform the test."
      },
      {
        "activityId": "Management Algorithms for Toxicity",
        "executionType": "Episode",
        "rationale": "Conditional workflows triggered by the occurrence of specific adverse events or toxicities."
      }
    ],
    "crossoverDesign": {
      "id": "crossover_1",
      "isCrossover": true,
      "numPeriods": 2,
      "numSequences": 2,
      "periods": [
        "Period 1",
        "Period 2"
      ],
      "sequences": [
        "AB",
        "BA"
      ],
      "washoutRequired": false,
      "sourceText": "washout period"
    },
    "footnoteConditions": [
      {
        "id": "fn_cond_1",
        "conditionType": "general",
        "text": "Original informed consent in screening for protocol participation.",
        "footnoteId": "fn_1",
        "structuredCondition": "sequence.precedes(all_activities, screening)",
        "appliesToActivityIds": [
          "Informed Consent"
        ],
        "sourceText": "Original informed consent in screening for protocol participation."
      },
      {
        "id": "fn_cond_2",
        "conditionType": "eligibility_conditional",
        "text": "Assessed during screening period and (re-enrollment if applicable).",
        "footnoteId": "fn_2",
        "structuredCondition": "timing.during(screening_period) || timing.during(re_enrollment)",
        "appliesToActivityIds": [
          "All screening assessments"
        ],
        "sourceText": "Assessed during screening period and (re-enrollment if applicable)."
      },
      {
        "id": "fn_cond_3",
        "conditionType": "timing_before",
        "text": "Within 14 days prior to first dose.",
        "footnoteId": "fn_3",
        "structuredCondition": "timing.before(first_dose, P14D)",
        "appliesToActivityIds": [
          "All pre-dose assessments"
        ],
        "sourceText": "Within 14 days prior to first dose."
      },
      {
        "id": "fn_cond_4",
        "conditionType": "timing_before",
        "text": "Including BP, HR, temperature, respiratory rate. Obtain vital signs at the screening visit and within 72 hours prior to first dose.",
        "footnoteId": "fn_5",
        "structuredCondition": "timing.before(first dose., PT72M)",
        "appliesToActivityIds": [
          "Vital Signs"
        ],
        "timingConstraint": "PT72H",
        "sourceText": "Including BP, HR, temperature, respiratory rate. Obtain vital signs at the screening visit and withi"
      },
      {
        "id": "fn_cond_5",
        "conditionType": "timing_before",
        "text": "Performed locally, within 14 days prior to randomization to include CBC w/differential and platelet count, LFTs (ALT, AST, total bilirubin, alkaline phosphatase), Alpha fetoprotein (AFP), BUN or serum urea level, albumin, creatinine, Ca+, Mg++, Na+, K+, Cl-, LDH, amylase, lipase, Glucose, TSH, Free T4, Free T3",
        "footnoteId": "fn_7",
        "structuredCondition": "procedure.location(local) && timing.before(randomization, P14D) && procedure.includes(CBC, LFTs, AFP, BUN, albumin, creatinine, electrolytes, LDH, amylase, lipase, glucose, TSH, Free_T4, Free_T3)",
        "appliesToActivityIds": [
          "Laboratory Assessments"
        ],
        "sourceText": "Performed locally, within 14 days prior to randomization to include CBC w/differential and platelet "
      },
      {
        "id": "fn_cond_6",
        "conditionType": "timing_after",
        "text": "Targeted examination must include at a minimum the following body systems: Cardiovascular, Gastrointestinal, Pulmonary, Skin",
        "footnoteId": "fn_8",
        "structuredCondition": "procedure.includes(Cardiovascular, Gastrointestinal, Pulmonary, Skin)",
        "appliesToActivityIds": [
          "Targeted Physical Examination"
        ],
        "sourceText": "Targeted examination must include at a minimum the following body systems: Cardiovascular, Gastroint"
      },
      {
        "id": "fn_cond_7",
        "conditionType": "timing_before",
        "text": "Serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) to be done within 24 hours prior to first dose, and then monthly regardless of dosing schedule",
        "footnoteId": "fn_9",
        "structuredCondition": "timing.before(first dose, and then monthly regardless of dosing schedule, PT24M)",
        "appliesToActivityIds": [
          "Pregnancy Test"
        ],
        "timingConstraint": "PT24H",
        "sourceText": "Serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) to be done wi"
      }
    ],
    "endpointAlgorithms": [
      {
        "id": "ep_1",
        "name": "Primary: Overall Survival (OS)",
        "endpointType": "Primary",
        "inputs": [
          "date of randomization",
          "date of death",
          "last known alive date"
        ],
        "timeWindow": {
          "reference": "randomization",
          "duration": "until death or last known alive date"
        },
        "algorithm": "OS = date of death - date of randomization",
        "successCriteria": "Subjects who are alive will be censored at the last known alive dates.",
        "sourceText": "OS is defined as the time from the date of randomization to the date of death due to any cause in all randomized subjects. Subjects who are alive will be censored at the last known alive dates."
      },
      {
        "id": "ep_2",
        "name": "Secondary: Objective Response Rate (ORR)",
        "endpointType": "Secondary",
        "inputs": [
          "BICR assessment",
          "RECIST 1.1 criteria",
          "confirmatory scan"
        ],
        "timeWindow": {
          "reference": "randomization",
          "duration": "every 8 weeks up to 48 weeks, then every 12 weeks"
        },
        "algorithm": "ORR = (subjects with confirmed CR + subjects with confirmed PR) / total randomized subjects",
        "successCriteria": "Confirmed CR or PR as determined by BICR based on RECIST 1.1",
        "sourceText": "ORR will be determined from assessment by a blinded independent central review (BICR) based on RECIST 1.1. ... Added requirement for confirmatory scan to be performed for CR/PR assessment of best over"
      },
      {
        "id": "ep_3",
        "name": "Secondary: Progression Free Survival (PFS)",
        "endpointType": "Secondary",
        "inputs": [
          "date of randomization",
          "date of first objective progression",
          "date of death",
          "BICR assessment",
          "RECIST 1.1 criteria"
        ],
        "timeWindow": {
          "reference": "randomization",
          "duration": "every 8 weeks up to 48 weeks, then every 12 weeks"
        },
        "algorithm": "PFS = (date of first objective progression or death) - date of randomization",
        "successCriteria": "Determined from assessments by a BICR based on RECIST 1.1",
        "sourceText": "PFS will be determined from assessments by a blinded independent central review (BICR) based on RECIST 1.1"
      },
      {
        "id": "ep_4",
        "name": "Secondary: Tumor PD-L1 expression and efficacy",
        "endpointType": "Secondary",
        "inputs": [
          "PD-L1 expression level",
          "OS",
          "ORR",
          "PFS"
        ],
        "timeWindow": {
          "reference": "baseline",
          "duration": "study duration"
        },
        "algorithm": "Correlation analysis between PD-L1 expression levels and efficacy endpoints (OS, ORR, PFS)",
        "successCriteria": "Evaluation of the relationship between expression and efficacy",
        "sourceText": "To evaluate the relationship between tumor PD-L1 expression and efficacy"
      }
    ],
    "derivedVariables": [
      {
        "id": "dv_1",
        "name": "Overall Survival (OS)",
        "variableType": "TimeToEvent",
        "sourceVariables": [
          "Date of Randomization",
          "Date of Death"
        ],
        "derivationRule": "Date of Death - Date of Randomization",
        "baselineDefinition": "Date of Randomization",
        "baselineVisit": "Day 1",
        "analysisWindow": "From randomization until death or last known alive date",
        "imputationRule": "Subjects who are alive will be censored at the last known alive dates",
        "unit": "Months"
      },
      {
        "id": "dv_2",
        "name": "Objective Response Rate (ORR)",
        "variableType": "Categorical",
        "sourceVariables": [
          "BICR-assessed tumor response",
          "Confirmatory scan"
        ],
        "derivationRule": "Proportion of subjects with a best overall response of CR or PR, requiring a confirmatory scan",
        "baselineDefinition": "Pre-treatment tumor imaging",
        "baselineVisit": "Screening",
        "analysisWindow": "Every 8 weeks (+/- 1 wk) up to 48 weeks, then every 12 weeks (+/- 1 wk)",
        "imputationRule": "Not specified",
        "unit": "Percentage"
      }
    ],
    "stateMachine": {
      "id": "sm_1",
      "initialState": "Screening",
      "terminalStates": [
        "Early Termination",
        "Completed"
      ],
      "states": [
        "Screening",
        "Randomization",
        "Treatment",
        "Follow Up",
        "Survival Follow Up",
        "Early Termination"
      ],
      "transitions": [
        {
          "fromState": "Screening",
          "toState": "Randomization",
          "trigger": "Progress to Randomization"
        },
        {
          "fromState": "Randomization",
          "toState": "Treatment",
          "trigger": "Progress to Treatment"
        },
        {
          "fromState": "Treatment",
          "toState": "Follow Up",
          "trigger": "Progress to Follow Up"
        },
        {
          "fromState": "Follow Up",
          "toState": "Survival Follow Up",
          "trigger": "Progress to Survival Follow Up"
        },
        {
          "fromState": "Treatment",
          "toState": "Early Termination",
          "trigger": "Subject exits to Early Termination"
        }
      ],
      "epochIds": {
        "Screening": "SCREENING",
        "Randomization": "RANDOMIZATION",
        "Treatment": "TREATMENT",
        "Follow Up": "FOLLOW_UP",
        "Survival Follow Up": "SURVIVAL_FOLLOW_UP",
        "Early Termination": "EARLY_TERMINATION"
      }
    },
    "dosingRegimens": [
      {
        "id": "dosing_1",
        "treatmentName": "Nivolumab",
        "frequency": "BID",
        "route": "Oral",
        "startDay": 1,
        "doseLevels": [
          {
            "amount": 240.0,
            "unit": "mg"
          },
          {
            "amount": 400.0,
            "unit": "mg"
          }
        ],
        "durationDescription": "2 weeks",
        "doseModifications": [
          "Subjects may be treated beyond disease progression under protocol-defined conditions"
        ],
        "sourceText": "enib as First-Line Treatment in Patients with Advanced Hepatocellular Carcinoma Investigational Product(s), Dose and Mode of Administration, Duration of Treatment with Investigational Product(s): Nivo"
      },
      {
        "id": "dosing_2",
        "treatmentName": "Sorafenib",
        "frequency": "BID",
        "route": "Oral",
        "startDay": 1,
        "doseLevels": [
          {
            "amount": 400.0,
            "unit": "mg"
          },
          {
            "amount": 240.0,
            "unit": "mg"
          }
        ],
        "durationDescription": "2 weeks",
        "sourceText": "tigational Product(s), Dose and Mode of Administration, Duration of Treatment with Investigational Product(s): Nivolumab 240 mg IV every 2 weeks until disease progression or unacceptable toxicity; Sor"
      },
      {
        "id": "dosing_3",
        "treatmentName": "for Injection",
        "frequency": "Q2W",
        "route": "Oral",
        "startDay": 1,
        "doseLevels": [
          {
            "amount": 100.0,
            "unit": "mg"
          },
          {
            "amount": 200.0,
            "unit": "mg"
          },
          {
            "amount": 10.0,
            "unit": "mg"
          }
        ],
        "durationDescription": "2 weeks",
        "sourceText": "both Investigational [Medicinal] Products (IP/IMP) and Non-investigational [Medicinal] Products (Non-IP/Non-IMP) as listed: Study Drug for CA209459 Medication Potency IP/Non-IP Nivolumab Solution for "
      },
      {
        "id": "dosing_4",
        "treatmentName": "Sorafenib Tablets",
        "frequency": "Q2W",
        "route": "Oral",
        "startDay": 1,
        "doseLevels": [
          {
            "amount": 200.0,
            "unit": "mg"
          },
          {
            "amount": 10.0,
            "unit": "mg"
          },
          {
            "amount": 100.0,
            "unit": "mg"
          }
        ],
        "durationDescription": "2 weeks",
        "sourceText": "oducts (IP/IMP) and Non-investigational [Medicinal] Products (Non-IP/Non-IMP) as listed: Study Drug for CA209459 Medication Potency IP/Non-IP Nivolumab Solution for Injection 100 mg (10 mg/mL) IP Sora"
      },
      {
        "id": "dosing_5",
        "treatmentName": "ETHICAL CONSIDERATIONS",
        "frequency": "QD",
        "route": "Oral",
        "startDay": 1,
        "doseLevels": [
          {
            "amount": 2.1,
            "unit": "g"
          }
        ],
        "sourceText": "ionship between tumor PD-L1 expression and efficacy Revised Protocol No.: 04 Date: 15-Jan-2019 20 5.0 Approved 930092650 5.0 v Clinical Protocol CA209459 BMS-936558 nivolumab 2 ETHICAL CONSIDERATIONS "
      },
      {
        "id": "dosing_6",
        "treatmentName": "Open Label",
        "frequency": "QD",
        "route": "Oral",
        "startDay": 1,
        "doseLevels": [
          {
            "amount": 10.0,
            "unit": "ml"
          }
        ],
        "sourceText": "9: Product Description / Class and Dosage Form Potency IP/Non-IMP Blinded or Open Label Packaging/ Appearance Storage Conditions (per label) Nivolumab Solution for Injectiona 100 mg (10 mg/mL) IP Open"
      },
      {
        "id": "dosing_7",
        "treatmentName": "Sorafenib Tabletsb",
        "frequency": "QD",
        "route": "Oral",
        "startDay": 1,
        "doseLevels": [
          {
            "amount": 200.0,
            "unit": "mg"
          },
          {
            "amount": 10.0,
            "unit": "mg"
          },
          {
            "amount": 100.0,
            "unit": "mg"
          }
        ],
        "sourceText": "Injectiona 100 mg (10 mg/mL) IP Open Label 10 mL per vial (5 or 10 vials/carton) Clear to opalescent colorless to pale yellow liquid. May contain particles 2 to 8C. Protect from light and freezing So"
      }
    ],
    "visitWindows": [
      {
        "id": "visit_6",
        "visitName": "Screening",
        "targetDay": -14,
        "windowBefore": 7,
        "windowAfter": 0,
        "isRequired": true,
        "visitNumber": 1,
        "epoch": "Screening Phase",
        "sourceText": "Screening Phase  Begins by establishing the subject’s initial eligibility and signing of the informed consent form"
      },
      {
        "id": "visit_1",
        "visitName": "Early Termination",
        "targetDay": null,
        "windowBefore": 0,
        "windowAfter": 0,
        "isRequired": true,
        "visitNumber": 2,
        "sourceText": "not have received prior systemic therapy for advanced HCC in keeping with the first-line setting of this study. Eligibility criteria are defined in the protocol. Study Drug: includes both Investigatio"
      },
      {
        "id": "visit_4",
        "visitName": "Visit 2",
        "targetDay": null,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 3,
        "sourceText": "discontinuation of therapy, safety will be assessed through post-treatment Follow Up visit 2 (~ 100 days from last dose). Survival status will be assessed every 3 months after follow up visits are com"
      },
      {
        "id": "visit_7",
        "visitName": "baseline",
        "targetDay": 0,
        "windowBefore": 1,
        "windowAfter": 1,
        "isRequired": true,
        "visitNumber": 4,
        "sourceText": "Subjects will be followed for drug-related toxicities until these toxicities resolve, return to baseline or are deemed irreversible. All adverse events will be documented for a minimum of 100 days aft"
      },
      {
        "id": "visit_8",
        "visitName": "eot",
        "targetDay": null,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 5,
        "sourceText": "Single Nucleotide Polymorphisms (SNPs) Whole blood will be collected from all subjects prior to treatment to generate genomic DNA for Single Nucleotide Polymorphism (SNP) analyses. Genes of interest i"
      },
      {
        "id": "visit_llm_8",
        "visitName": "Survival Follow-up",
        "targetDay": null,
        "windowBefore": null,
        "windowAfter": null,
        "isRequired": true,
        "visitNumber": 8,
        "epoch": "Survival Follow-up"
      },
      {
        "id": "visit_3",
        "visitName": "randomization",
        "targetDay": 1,
        "windowBefore": 0,
        "windowAfter": 0,
        "isRequired": true,
        "visitNumber": 7,
        "epoch": "Treatment Phase",
        "sourceText": "assessments will occur 8 weeks from the date of randomization (+/-1 wk), then every 8 weeks (+/- 1 wk) thereafter up to 48 weeks, then it will be every 12 weeks (+/- 1 week) until disease progression "
      },
      {
        "id": "visit_llm_4",
        "visitName": "Every 2 Weeks (On-treatment)",
        "targetDay": 15,
        "windowBefore": null,
        "windowAfter": null,
        "isRequired": true,
        "visitNumber": 4,
        "targetWeek": 2,
        "epoch": "Treatment Phase"
      },
      {
        "id": "visit_llm_5",
        "visitName": "Follow Up Visit 1 (X01)",
        "targetDay": 35,
        "windowBefore": 7,
        "windowAfter": 7,
        "isRequired": true,
        "visitNumber": 5,
        "targetWeek": 5,
        "epoch": "Follow Up Phase"
      },
      {
        "id": "visit_llm_6",
        "visitName": "Follow Up Visit 2 (X02)",
        "targetDay": 80,
        "windowBefore": 7,
        "windowAfter": 7,
        "isRequired": true,
        "visitNumber": 6,
        "targetWeek": 11,
        "epoch": "Follow Up Phase"
      },
      {
        "id": "visit_llm_7",
        "visitName": "Safety Assessment",
        "targetDay": 100,
        "windowBefore": null,
        "windowAfter": null,
        "isRequired": true,
        "visitNumber": 7,
        "targetWeek": 14,
        "epoch": "Follow Up Phase"
      },
      {
        "id": "visit_5",
        "visitName": "Follow-up",
        "targetDay": 365,
        "windowBefore": 7,
        "windowAfter": 7,
        "isRequired": true,
        "visitNumber": 12,
        "sourceText": "discontinuation of therapy, safety will be assessed through post-treatment Follow Up visit 2 (~ 100 days from last dose). Survival status will be assessed every 3 months after follow up visits are com"
      }
    ],
    "randomizationScheme": {
      "id": "randomization_1",
      "ratio": "1:1",
      "method": "Stratified randomization",
      "centralRandomization": true,
      "stratificationFactors": [
        {
          "id": "strat_llm_1",
          "name": "Etiology",
          "categories": [
            "HCV",
            "non-HCV (ie, HBV- and HCC with no history of hepatitis virus infection)"
          ],
          "isBlocking": false
        },
        {
          "id": "strat_llm_2",
          "name": "Vascular invasion &/or extrahepatic spread",
          "categories": [
            "present",
            "absent"
          ],
          "isBlocking": false
        },
        {
          "id": "strat_llm_3",
          "name": "Geography",
          "categories": [
            "Asia",
            "Non-Asia"
          ],
          "isBlocking": false
        }
      ],
      "sourceText": "Clinical Protocol\nCA209459\nBMS-936558\nnivolumab\nSYNOPSIS\nClinical Protocol CA209459\n(CheckMate 459: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 459)\nProtocol Title: A Randomized, Multi-"
    }
  }
}